What question did this study set out to answer?

This review aims to evaluate current combination therapeutic strategies for managing hidradenitis suppurativa (HS).

May 22, 2026Sage Open Chronic DiseaseOpen Access

Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives

View Full Paper

Ask AI

Bookmark

Authors

Narrative review synthesizes evidence on combination therapies in hidradenitis suppurativa, highlighting treatment advancements.

This review aims to evaluate current combination therapeutic strategies for managing hidradenitis suppurativa (HS).
Conducted a systematic search of PubMed, Embase, and Cochrane databases from 2009 to July 2025.
Included randomized and nonrandomized trials, cohort studies, and case series with at least 10 patients.
Evaluated multimodal approaches such as antibiotics plus biologics, small molecules, and laser therapies.
Biologics such as adalimumab and secukinumab improve long-term outcomes when combined with antibiotics or during surgery.
Antibiotics like clindamycin–rifampicin provide good but temporary benefits; best used as preparatory steps for long-term treatments.
Adjunctive measures including wound care and metabolic interventions are necessary for comprehensive disease management.

Carugno et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark